Clinical trial
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
NCT00120939 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00120939 |
|---|---|
| Title | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer |
| Official title | Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium |
| Enrollment | 25 |
| First posted | Jul 19, 2005 |
| Last update posted | Apr 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: